Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast
Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients
with undergoing percutaneous coronary intervention. It is anticipated that approximately 280
patients will be randomized into the study in a 1:1 ratio to 400 mg APX-115 (Isuzinaxib
hydrochloride) or placebo arm.